Drugging the Undruggable Cancer Targets

Presented by Dr. Ming Liu, Senior Vice President of Biology and Pharmacology at ChemPartner Abstract:

Cancer is a multifactorial disease, and its genesis and progression are extremely complex. The scope of precision oncology is rapidly expanding to address previously undruggable targets. The term “undruggable” was used to describe proteins that could not be targeted pharmacologically. Many targets in cancer research fall into this category, including KRAS, which has eluded researchers for more than 30 years until recent landmark discoveries of AMG 510, MRTX 849, and BI 1701963. As clinical trials are vigorously advanced, efficacy, safety, resistance, and combination strategies are being carefully evaluated for those drug candidates. In addition to KRAS, there are other challenging targets such as P53, MYC, fusion transcription factors, immuno-suppressors,…etc.

The focus of this webinar is to provide an overview of strategies in drugging some perceived undruggable targets, with stories and case studies by scientists who strive to find these medicines and fill unmet patient needs.

Experienced in overcoming prior hurdles to find effective antagonists against cancer, as a R&D CRO, ChemPartner has utilized a wide range of integrated approaches such as medicinal chemistry, antibody-drug conjugates, monoclonal antibodies, in vitro biology assays, cell biology, immuno-oncology, pharmacology, and combination therapy to identify and tackle the problems that surround drug development for “undruggable” targets.

Keep watching…

Assay Platforms for PROTAC in Drug Discovery and Beyond

Assay Platforms for PROTAC in Drug Discovery and Beyond

Presented by Yuzhou Xu, Senior Director of Biology and Pharmacology at ChemPartner. Abstract: Discover a groundbreaking webinar delving into the in vitro assays for proteolysis targeting chimera (PROTAC). PROTACs are being developed more and more for many kinds of...

EEG Analysis and Animal Behavior in CNS Drug Development

EEG Analysis and Animal Behavior in CNS Drug Development

Presented by Ruiben Feng, PhD, Executive Director, Neurobiology and Neuropharmacology at Shanghai ChemPartner. Abstract: EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and...

Headquarters

1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203

w

Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000

contact@chempartner.com